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Hypertension represents one of the most important controllable risk factors for global morbidity and mortality (1 ) . Genetic predisposition and environmental factors contribute to the pathogenesis of hypertension and play key roles for prevention and therapy. Although essential hypertension is thought to be heritable in about 30% to 50% of cases, genetic factors determining predisposition to hypertension and response to therapy are difficult to identify, because the effect of single alleles depends on complex gene-gene and gene-environment interactions (2, 3 ) . This complex interaction is exemplified by the still controversial role of salt sensitivity in hypertensive patients (4 ) . About 20%-40% of patients are salt sensitive, as defined by a Ͼ10% increase or decrease of the mean blood pressure upon salt loading and salt restriction, respectively. Salt sensitivity is associated with ethnicity, age, family history of hypertension, renal insufficiency, and potassium deficiency (5) (6) (7) . Genetic analyses have indicated a central importance of renal sodium handling in the determination of salt sensitivity, and particularly in the function of the renal dopamine D1 receptor in the proximal tubule (8 -11 ) . In the setting of increased dietary sodium intake, renal dopamine receptors regulate Ͼ50% of sodium excretion (12 ) . Interestingly, in salt-sensitive hypertensive patients consuming a high sodium diet, urinary dopamine excretion is lower than in non-salt-sensitive patients (13, 14 ) .
The function of the dopamine D1 receptor in the renal proximal tubule depends on the interaction with G-protein receptor kinase 4 (GRK4). 4 In different animal models, G protein-coupled receptor kinase 4 (GRK4) gene polymorphisms caused an uncoupling of the dopamine D1 receptor from its G-protein enzyme complex, leading to a decreased renal dopamine effect and thereby to an increased sodium reabsorption, eventually leading to hypertension (15 ) . In the coding region of the GRK4 gene, 6 single-nucleotide polymorphisms (R65L, A142V, A486V, V247I, A253T, and G562D) have been identified (16 ) and the GRK4 gene locus (4p16.3) linked to hyper-tension and salt sensitivity (17, 18 ) . Three GRK4 variants, R65L (nucleotide change CGT to CTT), A142V (nucleotide change GCC to GTC), and A486V (nucleotide change GCG to GTG) were associated with salt sensitivity. Human GRK4 142V transgenic mice were hypertensive even on with normal sodium intake, whereas human GRK4 486V transgenic mice develop hypertension only on a high-salt diet (19 ) . Polymorphisms at all 3 sites (65L, 142V, and 486V) predicted salt sensitivity in a population of Japanese hypertensive patients with an accuracy of 94% (20 ) . In another study, normotensive young adults homozygous for the haplotype 65L-142V-486A showed a greater increase in blood pressure with age than those homozygous for the most common R65-A142-A486 haplotype (21 ) . These findings underline the role of GRK4 polymorphisms in hypertension in humans, and determination of GRK4 gene variants might help for early diagnosis, general risk stratification, and prediction of salt sensitivity. However, the impact of GRK4 polymorphism on response to antihypertensive therapy is not known.
The aim of the present study was to investigate whether blood pressure control in patients with arterial hypertension was different for patients with GRK4 polymorphisms at R65L, A142V, and A486V than for those without these polymorphisms. We therefore determined antihypertensive therapy, blood pressure control, and single-nucleotide polymorphism genotypes at the 3 GRK4 loci in patients with known arterial hypertension who were in regular outpatient treatment.
Materials and Methods

STUDY DESIGN AND PATIENTS
Approval for this project was obtained from the ethics committee of the local legal authority (Canton of Zurich). All patients gave written informed consent to participate in the study. We recruited 100 consecutive patients with treated or untreated essential hypertension in the medical outpatient clinic (Medical Policlinic, Division of Internal Medicine) at the University Hospital of Zurich. Exclusion criteria were moderate to severe renal insufficiency (creatinine clearance Ͻ50 mL/min), excessive alcohol consumption (more than 2 standard drinks containing 12 g pure alcohol per standard drink), drug abuse, and regular intake of steroids or nonsteroidal antiinflammatory drugs. Blood pressure was measured with a sphygmomanometer at least 2 times before enrollment. To investigate the response to antihypertensive therapy without influencing medical management, none of the investigators were the treating doctors and antihypertensive therapy was not changed for this study. At the time point of inclusion, the investigators were unaware of the current antihypertensive treatment of the patients. The antihypertensive therapy previously established by the treating doctor and the blood pressure were correlated with GRK4 polymorphism. Blood was drawn for GRK4 genotyping (5-mL EDTA tubes) and clinical laboratory analyses (10-mL heparinized tubes) using BD Vacutainer® Blood Collection Tubes (Becton Dickinson). Plasma was immediately centrifuged for approximately 10 min at 2500g and the supernatant was carefully transferred into a labeled plastic container (polyethylene vial) and stored at Ϫ20°C until all 100 patients were enrolled in the study.
GENETIC ANALYSIS
Blood was collected in 5-mL EDTA tubes (Becton Dickinson). DNA was isolated by standard rapid lysis technique using the Qiagen QIAamp blood kit (Qiagen). The polymorphisms were detected using highresolution melting curve analysis with FRET (fluorescence resonance energy transfer) on a Light Cycler real-time PCR machine 2.0 using the LC-DNA Master HyProbes mastermix (Roche). Primers and probes are reported in Table 1 in the Data Supplement that accompanies the online version of this report at http:// www.clinchem.org/content/vol60/issue12. The cycling conditions were 94°C at 30 s, 45 cycles of 94°C for 0 s, 50°C for 4 s, and 72°C for 4 s, followed by denaturation for 1 min at 95°C and high-resolution melting curve analysis from 42°C to 75°C.
All 3 genotyping assays (R65L, A142V, and A486V) were validated before analyzing the current study. To verify the genotyping results, at least 1 DNA of each genotype for the 3 polymorphisms was sequenced by Sanger sequencing. Reproducibility was investigated by reanalysis of these sequenced DNAs. These genomic DNAs were subsequently used as positive controls for the genotyping procedures, in which all 3 genotypes were used as positive controls during the batchwise genotyping procedure for each polymorphism.
STATISTICAL ANALYSIS
Data are reported as mean Ϯ SD. Variables between groups were determined by unpaired t-test, 2 test, or Mann-Whitney U-test. Multiple regression analysis (SigmaPlot, 11.0) was performed to consider possible confounding effects. Statistical significance was defined with ␣ ϭ 0.05. Hardy-Weinberg equilibrium was confirmed separately for whites and for the entire cohort with a 2 test (␣ ϭ 0.05, 1 df).
Results
BASELINE CHARACTERISTICS
Among the 100 patients included in the study, 51% were male and 75% white. The mean age was 58 (12) years and the body mass index (BMI) was 28 (4) kg/m 2 .
Mean blood pressure at baseline was 145 (23) 
SINGLE-LOCUS ANALYSIS
First, we investigated the impact of single homozygous GRK4 minor variants 65L, 142V, and 486V on hypertension control and need for antihypertensive medication. In this patient population under antihypertensive therapy, blood pressure values were not significantly influenced by single homozygous GRK4 variants (see online Supplemental Table 2 ). There was an increased requirement for antihypertensive medication in homozygous carriers of 65L (2.47 vs 1.96, P ϭ 0.084), 142V (2.38 vs 1.97, P ϭ 0.146), and to lesser degree, 486V (2.18 vs 2.04, P ϭ 0.668) to reach the same blood pressure than in heterozygous or wild-type carriers, although these differences were not statistically significant.
HAPLOTYPE ANALYSIS
On the basis of the single-locus results, we analyzed the impact of a combination of GRK4 variants on hypertension control. Patients with homozygous double mutations of 65L and 142V (n ϭ 17) required significantly more antihypertensive medication to reach the same blood pressure than patients with single-locus mutations (2.59 vs 1.95, P ϭ 0.043; see the distribution of antihypertensive subclasses shown in online Supplemental Table 3 and online Supplemental Fig. 1 ). Among patients with combined homozygous 65L and 142V variants, 94% needed 2 or more antihypertensives, whereas this was the case for only 63% of patients with heterozygous or wild-type GRK4 alleles (16/17 patients vs 52/83 patients, P ϭ 0.011, Fig. 1) . Importantly, the presence of combined 65L and 142V variants was not associated with significant differences in terms of sex, ethnic background, age, BMI, nicotine consumption, and alcohol intake. Systolic and diastolic blood pressure was similar in the 2 groups (Table 2 ). Diuretics were the major drug class leading to the higher need for antihypertensives in the double-homozygous variant 65L/142V group. A significantly higher percentage of patients with the double-homozygous 65L/142V variant were on diuretic therapy than patients with the heterozygous or wild-type alleles (76% vs 47%, P ϭ 0.021, Fig. 2A) . Furthermore, the use of diuretics per day was significantly higher in homozygous 65L/142V patients (0.82 vs 0.49, P ϭ 0.029, Fig. 2B ). A subclass effect was observed for thiazides and thiazide-like diuretics, with 0.71 per day for homozygous carriers of doublemutation 65L and 142V and 0.45 per day for heterozygous and wild-type carriers (P ϭ 0.050). Thiazides and Nicotine abuse, n (%) 31
Habitual alcohol intake, n (%)
Creatinine clearance Ͼ60 mL/min, n (%) 93
Antihypertensive medication, n (%) 94 a Age, BMI, and blood pressure are presented as mean (SD). Dyslipidemia was defined as triglycerides/total cholesterol Ͼ5 or statin therapy, and sensible alcohol consumption was defined as 1-2 units (standard drinks containing 12 g pure alcohol) per day. b Two patients with more than 2 units per day. thiazide-like diuretics such as chlorthalidone and indapamide were the most commonly used diuretic medication (95%), with an additional 2 patients with loop diuretic, 1 patient with potassium-sparing diuretic, and 3 patients with additional potassium-sparing diuretic. Homozygous carriers of all 3 variant alleles (n ϭ 9) did not require more antihypertensives than heterozygous and wild-type carriers (2.33 vs 2.03, P ϭ 0.526), showing no influence of the A486V allele on blood pressure control (see online Supplemental Table  4 and online Supplemental Fig. 2 ).
REGRESSION ANALYSIS
Finally, multiple regression analysis of all study parameters was performed to assess possible confounding factors on the use of diuretic therapy. A significant association of the 65L/142V polymorphism with the use of diuretic therapy was confirmed (Table 3 ). In addition, we found a significant association of diuretics with diabetes mellitus. This might be explained by the recommended and common use of diuretics as part of the antihypertensive treatment in diabetic patients (22) (23) (24) .
Discussion
In this study we investigated the association of the 3 GRK4 variants R65L, A142V, and A486V on blood pressure control in individuals with hypertension. Although there were no significant differences in baseline characteristics between patients with different GRK4 variants, we found that homozygous carriers of combined R65L and A142V variants needed more antihypertensive therapy to reach the same mean arterial pressure than did heterozygous and wild-type carriers. Moreover, among the different antihypertensive drug classes, we observed an increased need for diuretics, particularly for thiazide and thiazide-like diuretics. Furthermore, we observed a higher ␤-blocker use in patients with GRK4 polymorphisms R65L, A142V, and A486V and especially for haplotype 65L/142V. These results support the earlier observation that GRK4 variants affect blood pressure response to ␤-blockers (25 ) , and that hypertensive patients with haplotype 65L/142V show a reduced response to ␤-blocker therapy (26 ) . Although a recent study showed evidence that GRK4 variants have an impact on agents acting on the renin-angiotensin system (27 ) , our data did not show an association between GRK4 polymorphisms R65L, A142V, and A486V and therapy with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II (ATII) antagonists.
The GRK4 variants are associated with a blunted dopamine effect, which is also associated with a higher salt sensitivity and impaired renal sodium excretion. Our data suggest that patients with homozygous variants of R65L and A142V may particularly benefit from diuretics compared to patients with heterozygous or wild-type variants of this allele. Because diuretic therapy is rarely the first choice when treating patients with essential hypertension, the higher number of total antihypertensives in these patients might indirectly reflect salt sensitivity. Presumably, in these patients blood pressure reduction was inadequate because diuretics were not used in the first line. However, because data about the order or introduction of the antihypertensives were not available, we cannot support our hypothesis from the time course of the blood pressure reduction. Furthermore, we cannot exclude that other salt-independent effects of GRK4 variants might lead to blood pressure therapy resistance. In this case the higher number of patients treated with diuretics might be related to the common use of diuretics in combination with ACE-inhibitors and angiotensin receptor blockers. Therefore, our findings need confirmation in a prospective study with sequential introduction of the different antihypertensive drug classes.
A strength of this study is the random recruitment of the study population in a medical outpatient clinic, which reflects an unbiased clinically relevant patient population. Importantly, medical evaluation including medical history and blood pressure measurement was performed by the investigators-otherwise not involved in patient care-and unaware of the GRK4 genotyping.
Although the results are unambiguous, there are some study limitations. Our main finding about the need for diuretics in the patient homozygous for the GRK4 65L and 142V alleles remains an association without any information on direct or indirect causality, and we cannot provide any evidence about the potential mechanism. Nevertheless, some data from the literature allow us to speculate on the mechanisms. GRK4 polymorphisms decrease the dopamine effect via modulation of the dopamine D1 receptor in the renal proximal tubule, leading to an increased salt absorption (15 ) . Inhibition of the renal Na ϩ /Cl Ϫ cotransporter in the distal tubule by thiazides might compensate for this Creatinine clearance Ͼ60 mL/min 0.676
Habitual alcohol intake 0.851 effect and therefore explain the effectiveness of diuretics in these patients. The choice of an ideal antihypertensive drug for the treatment of arterial hypertension is currently handled by a trial-and-error approach. Our findings might represent an important step forward to predict response to antihypertensive therapy and to implement the principles of personalized medicine in hypertension. To confirm the clinical applicability, the efficacy, and the costeffectiveness of this approach, the results need to be validated in a prospective interventional study. 
